Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-96,339
Closed -$2.8M 128
2024
Q2
$2.8M Sell
96,339
-3,824
-4% -$105K 1.22% 27
2024
Q1
$2.78M Buy
100,163
+26,891
+37% +$746K 1.24% 21
2023
Q4
$2.11M Buy
73,272
+1,372
+2% +$41.5K 1% 41
2023
Q3
$2.38M Sell
71,900
-247
-0.3% -$8.73K 1.22% 33
2023
Q2
$2.65M Buy
+72,147
New +$2.81M 1.27% 25
2021
Q2
Sell
-29,680
Closed -$1.07M 121
2021
Q1
$1.07M Buy
29,680
+1,300
+5% +$46.2K 0.63% 46
2020
Q4
$1.04M Sell
28,380
-1,174
-4% -$43.1K 0.62% 45
2020
Q3
$1.03M Buy
29,554
+2,265
+8% +$79.4K 0.74% 42
2020
Q2
$847K Buy
27,289
+2,011
+8% +$68.3K 0.76% 37
2020
Q1
$782K Sell
25,278
-48
-0.2% -$1.64K 1.37% 18
2019
Q4
$941K Sell
25,326
-210
-0.8% -$7.48K 0.53% 50
2019
Q3
$871K Sell
25,536
-1,265
-5% -$46K 0.51% 46
2019
Q2
$1.1M Buy
26,801
+448
+2% +$17.8K 0.66% 42
2019
Q1
$1.06M Buy
26,353
+2,746
+12% +$110K 0.65% 37
2018
Q4
$978K Buy
23,607
+2,474
+12% +$103K 0.89% 20
2018
Q3
$884K Hold
21,133
0.61% 34
2018
Q2
$727K Buy
21,133
+4,427
+26% +$151K 0.56% 36
2018
Q1
$563K Buy
16,706
+1,159
+7% +$39.8K 0.48% 46
2017
Q4
$534K Buy
+15,547
New +$530K 0.39% 51

Other funds holding PFE

G&S Capital's PFE Position: Q3 2024 in Review

G&S Capital sold out of Pfizer (PFE) in Q3 2024, closing a stake of 96,339 shares — an estimated $2.8M sold.

G&S Capital first reported a position in PFE in Q4 2017 and held it in 19 quarters. The position peaked at $2.8M in Q2 2024. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.

  • G&S Capital reported no remaining Pfizer position as of Q3 2024 after selling out during the quarter.
  • G&S Capital sold 96,339 Pfizer shares in Q3 2024, an estimated $2.8M.
  • G&S Capital first reported a position in Pfizer in Q4 2017 and held it in 19 quarters.
  • G&S Capital's Pfizer position peaked at $2.8M in Q2 2024.
  • 2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.

Based on G&S Capital's 13F filing for Q3 2024, filed 16 Oct 2024.